Continuous glucose monitoring (CGM) has revolutionized diabetes management, offering a real-time window into glucose trends rather than relying on isolated blood sugar readings. Among the options available, Dexcom CGMs distinguish themselves through a seamless blend of innovation, user-centric design, and robust support systems.
Their reputation extends beyond the device hardware; a comprehensive ecosystem of software, integrations, and community trust underpins their leading status in the CGM market. Embracing both technological prowess and empathetic design, Dexcom has nurtured an experience that aligns with modern expectations for health devices.
Seamless integration with smartphones, smartwatches, and insulin delivery systems offers unmatched convenience for users. Meanwhile, rigorous clinical validation and ongoing feature enhancements have secured Dexcom’s place as a trailblazer in both consumer trust and medical efficacy. Let's look at What sets Dexcom CGMs apart.
Dexcom’s evolution in continuous glucose monitoring is reflected in its expanding product portfolio. Each model builds on the strengths of its predecessors while introducing targeted improvements.
This diversity ensures that users can select a device that best aligns with their lifestyle, budget, and clinical needs.
| Model | Wear Duration | Warm-Up Time | Calibration Required | MARD Accuracy | Key Features | Intended Users |
| G6 | 10 days | 2 hours | No | ~9% | Integration with pumps, customizable alerts, Clarity reports | Adults & children (2+) |
| G7 | 10 days | 30 minutes | No | ~8% | Smaller size, faster warm-up, improved adhesive, predictive alerts | Adults & children (2+) |
| Stelo (OTC) | 15 days* | 30 minutes* | No | TBD | Over-the-counter, designed for non-insulin Type 2 & wellness | Adults only |
| ONE | 10 days | 2 hours | No | ~9% | Affordable CGM option, real-time readings | Select international markets |
*Expected values based on Dexcom announcements; subject to regulatory approval.
The Dexcom G6 remains a trusted choice for many due to its blend of accuracy and convenience. With a 10-day sensor wear period and no need for routine finger-stick calibrations, it set the standard for modern CGMs when introduced.
The transmitter is reusable for up to three months, and the system integrates with several insulin pumps, including the Tandem t:slim X2. Alerts for both highs and lows are customizable, and data sharing allows real-time monitoring by caregivers.
The Dexcom G7 builds on the G6’s success with a 60% smaller sensor-transmitter profile and a faster warm-up time of just 30 minutes. While still offering 10-day wear, the G7 improves adhesive comfort and delivers slightly better accuracy, with Mean Absolute Relative Difference (MARD) scores often under 9%.
Its redesigned mobile app features more intuitive graphing, enhanced predictive alerts, and simplified sensor application, qualities that appeal to both experienced and first-time CGM users.
Announced for launch in 2025, the Dexcom Stelo is designed as the company’s first over-the-counter CGM in the United States. Targeted primarily at people with Type 2 diabetes who do not use insulin, Stelo will offer a more affordable entry point while still delivering continuous glucose data and app integration.
It represents a strategic expansion into preventive health and lifestyle management, beyond insulin-dependent diabetes.
The Dexcom ONE is available in select international markets as a more affordable CGM alternative. While it lacks some advanced integration features, it delivers the core benefits of continuous glucose monitoring, including real-time readings and alerts.
Its simplified design makes it a strong option for users seeking accuracy without the cost of premium-tier models.
Though not a sensor itself, Dexcom Clarity is an integral part of the Dexcom ecosystem. It provides in-depth reports, trend analysis, and sharing capabilities for healthcare providers.
This tool allows patients and clinicians to track time-in-range, evaluate therapy adjustments, and visualize progress over time, critical elements in optimizing diabetes management.
Dexcom has consistently stayed ahead in CGM technology by investing in sensor accuracy, convenience, and reliability. Their product development emphasizes reducing calibration burdens, extending wear duration, and improving signal stability, which ultimately enhances the user experience and clinical outcomes.
From the outset, Dexcom’s G6 model made headlines for eliminating the need for finger-stick calibrations. This marked a revolutionary shift, as users no longer had to rely on painful routine checks to validate sensor readings.
Instead, factory calibration ensured reliable accuracy from day one, a feature that continues in newer models. Clinical studies have confirmed that this calibration-free approach sustains strong accuracy comparable to traditional methods.
Dexcom devices typically offer up to 10 days of sensor wear, reducing the frequency of sensor changes for users. Meanwhile, enhancements in sensor chemistry and signal processing contribute to fewer dropouts and more consistent glucose trend lines.
These innovations minimize the risk of missed alerts and allow full reliance on continuous data.
To deliver smoother, more dependable readings, Dexcom employs powerful algorithms that interpret raw sensor data thoughtfully. This leads to reduced noise and fewer false alarms, therefore delivering a level of reliability that empowers users to make confident decisions about insulin dosing, meal timing, or physical activity.
Efficient Bluetooth transmission ensures seamless communication between the sensor transmitter and paired devices, all while conserving battery life. Users enjoy reliable data streams without worrying about frequent recharging, and the discreet size of the transmitter keeps the CGM unobtrusive for daily wear.
Dexcom’s leadership in continuous glucose monitoring extends well beyond the accuracy of its sensors. The company has invested heavily in building a connected ecosystem that transforms raw glucose data into actionable insights.
This ecosystem links hardware, software, and cloud-based analytics into a unified experience, reducing the daily cognitive load of diabetes management and enhancing the user’s ability to respond in real time.
The Dexcom app is the primary interface for users, offering real-time glucose readings, 24-hour trend graphs, and predictive alerts that warn of impending highs or lows before they occur. Its layout is designed for quick interpretation, with color-coded zones and customizable thresholds to match individual therapy goals.
The app also stores historical data, enabling users to spot recurring patterns related to meals, exercise, or medication schedules. This historical view is essential for those working closely with healthcare providers to refine treatment strategies.
In addition to smartphones, Dexcom integrates seamlessly with popular smartwatches such as Apple Watch, Garmin, and select Wear OS devices. This allows users to check their glucose at a glance without unlocking their phone, a feature particularly valuable during physical activity, driving, or professional settings where discretion matters.
Real-time watch-face complications update continuously, ensuring that glucose data is always within sight, even without direct phone access.
Dexcom’s Share feature allows users to send their real-time glucose readings to up to ten followers via the Dexcom Follow app. This capability is a lifeline for parents of children with diabetes, partners, or caregivers of elderly patients.
The system can deliver urgent alerts to followers even if the user’s own device is on silent, ensuring that hypoglycemia or hyperglycemia events never go unnoticed. This connected care approach blends personal independence with the security of a support network.
Dexcom’s open approach to third-party integration has made it a preferred CGM for hybrid closed-loop systems. Partnerships with insulin pump manufacturers such as Tandem Diabetes Care (t:slim X2) and Insulet (Omnipod 5) enable automated insulin dosing adjustments based on continuous glucose input.
This not only smooths glucose variability but also reduces the mental and emotional burden of frequent dosing decisions.
Through platforms like Dexcom Clarity, users and healthcare providers can review weekly summaries, trend graphs, and time-in-range statistics. These reports can be shared securely via email or integrated into electronic medical record systems.
The ability to generate long-term data insights supports more precise therapy adjustments and aligns with modern, data-driven healthcare practices.
For a medical device that directly influences treatment decisions, regulatory approval is the foundation of patient trust. Dexcom has consistently demonstrated its ability to meet and exceed the stringent safety, accuracy, and manufacturing standards set by global regulatory agencies.
These achievements not only validate the technology but also support broader reimbursement and clinical adoption across diverse healthcare systems.
In the United States, the Food and Drug Administration (FDA) has cleared multiple Dexcom CGM systems, including the G6, G7, and the soon-to-launch Stelo, for use in adults and children as young as two years old. Each new generation undergoes rigorous evaluation for accuracy, stability, and user safety before receiving market clearance.
Beyond the U.S., Dexcom devices hold CE Mark certification in the European Union, reflecting compliance with the EU’s Medical Device Regulation (MDR). These approvals enable distribution in more than 50 countries and signify adherence to internationally recognized performance benchmarks.
Clinical accuracy is often measured by the Mean Absolute Relative Difference (MARD), which compares sensor readings to laboratory glucose measurements. Dexcom’s G6 achieved a MARD of approximately 9%, while the G7 improved further, reaching values close to 8% in adult trials.
This level of precision places Dexcom among the top performers in the CGM category, allowing users and clinicians to make dosing and lifestyle decisions with confidence.
Dexcom’s clinical reliability is reinforced by a substantial body of peer-reviewed research. Studies have demonstrated that use of Dexcom CGMs can significantly reduce time spent in hypoglycemia, increase time-in-range, and improve HbA1c levels in both Type 1 and insulin-treated Type 2 diabetes populations.
Research in Diabetes Care and the Journal of Diabetes Science and Technology confirms Dexcom’s benefits across pediatric, pregnant, and older adult populations, demonstrating consistent accuracy and usability.
The strength of this evidence base has earned Dexcom a place in major diabetes management guidelines. Organizations such as the American Diabetes Association (ADA) and the Association of Diabetes Care & Education Specialists (ADCES) recommend CGM use for most people with insulin-dependent diabetes from the point of diagnosis.
In some cases, guidelines now endorse CGM use for non-insulin-treated individuals at high risk for glucose variability, an expansion that opens the door for Dexcom’s newer OTC products like Stelo.
Dexcom CGMs continue to stand out in an increasingly competitive market by combining proven accuracy, ease of use, and seamless integration with digital health tools. Their balance of clinical reliability, user-friendly design, and strong customer support keeps them at the forefront of continuous glucose monitoring technology.
These strengths ensure Dexcom remains a trusted choice for individuals seeking both day-to-day convenience and long-term health benefits. As the CGM landscape evolves, other manufacturers are introducing devices with their own unique strengths, from extended wear sensors to fully disposable models.
Comparing features such as alert customization, device integration, wear duration, and affordability will be key in identifying the most effective solutions for different lifestyles. The Best Continuous Glucose Monitors of 2025 examines how Dexcom measures up against emerging competitors.
